Caribou Biosciences (CRBU) Stock Statistics & Valuation Metrics

Caribou Biosciences has a market cap or net worth of $47.64M. The enterprise value is $92.08M.

Market Cap

$47.64M

Enterprise Value

$92.08M

Caribou Biosciences has 107,207,510 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

107,207,510

Owned by Insiders

4.31%

Owned by Institutions

20.99%

Caribou Biosciences’s return on equity (ROE) is -1.21 and return on invested capital (ROIC) is -89.77%.

Return on Equity (ROE)

-1.21

Return on Assets (ROA)

-0.84

Return on Invested Capital (ROIC)

-89.77%

Return on Capital Employed (ROCE)

-0.91

Revenue Per Employee

115.04K

Profits Per Employee

-1.53M

Employee Count

97

Asset Turnover

0.06

Inventory Turnover

0.00

The current PE Ratio of Caribou Biosciences is -0.40. Caribou Biosciences’s PEG ratio is -0.01.

PE Ratio

-0.40

PS Ratio

5.64

PB Ratio

0.58

Price to FCF

-0.48

Price to Operating Cash Flow

-0.48

PEG Ratio

-0.01

In the last 12 months, Caribou Biosciences had revenue of 11.16M and earned -148.13M in profits. Earnings per share was -1.59.

Revenue

11.16M

Gross Profit

7.51M

Operating Income

-136.19M

Pretax Income

-148.68M

Net Income

-148.13M

EBITDA

-145.03M

Earnings Per Share (EPS)

-1.59

In the last 12 months, operating cash flow was -95.78M and capital expenditures 28,000, giving a free cash flow of -95.75M billion.

Operating Cash Flow

-95.78M

Free Cash Flow

-95.75M

Free Cash Flow per Share

-0.86

Caribou Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-217.36%

Earnings Yield

-249.19%

Beta

2.25

52-Week Price Change

-81.19%

50-Day Moving Average

1.02

200-Day Moving Average

1.62

Relative Strength Index (RSI)

26.20

Average Volume (3m)

2.63M

Caribou Biosciences upcoming earnings date is Mar 11, 2027, TBA (Not Confirmed).

Last Earnings Date

Aug 13, 2026

Next Earnings Date

Mar 11, 2027

Ex-Dividend Date

―

Caribou Biosciences as a current ratio of 5.71, with Debt / Equity ratio of 22.29%

Current Ratio

5.71

Quick Ratio

5.71

Debt to Market Cap

0.00

Net Debt to EBITDA

-0.10

Interest Coverage Ratio

0.00

In the past 12 months, Caribou Biosciences has paid -550.00K in taxes.

Income Tax

-550.00K

Effective Tax Rate

0.00

Caribou Biosciences EV to EBITDA ratio is -0.43, with an EV/FCF ratio of -0.46.

EV to Sales

4.44

EV to EBITDA

-0.43

EV to Free Cash Flow

-0.46

EV to Operating Cash Flow

-0.46

Caribou Biosciences has $112.31M in cash and marketable securities with $26.66M in debt, giving a net cash position of $85.66M billion.

Cash & Marketable Securities

$112.31M

Total Debt

$26.66M

Net Cash

$85.66M

Net Cash Per Share

$0.80

Tangible Book Value Per Share

$0.97

Gross margin is 91.72%, with operating margin of -1374.43%, and net profit margin of -1307.48%.

Gross Margin

91.72%

Operating Margin

-1374.43%

Pretax Margin

-1314.50%

Net Profit Margin

-1307.48%

EBITDA Margin

-1329.65%

EBIT Margin

-1001.90%

The average price target for Caribou Biosciences is $3.75, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target

$3.75

Price Target Upside

810.19% Upside

Analyst Consensus

Moderate Buy

Analyst Count

6

Revenue Growth Forecast

10.02%

EPS Growth Forecast

39.66%

Smart Score

5

AI Score

41